[生性慢性阻塞性肺病:一篇评论]
1Pirogov Russian National Research Medical University.
Terapevticheskii arkhiv
|December 30, 2023
概括
慢性阻塞性肺病 (COPD) 涉及呼吸道炎症和重塑. 异性COPD是一种独特的亚型,可能受益于针对性疗法,如单克隆抗体,改善预后.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 慢性阻塞性肺病 (COPD) 是一个重要的全球健康问题,其特点是空气流量限制和气道改造.
- 一部分COPD患者 (20-40%) 呈现出类似于喘的异性气道炎症,这种表型与更严重的气道改造有关.
研究的目的:
- 审查在COPD中驱动eosinophilia的机制.
- 评价血液和唾液中异氨基的有用性,作为预后和治疗指导的生物标志物.
- 讨论单克隆抗体治疗的潜力,以向T2内型炎症在eosinophilic COPD中.
主要方法:
- 文献综述侧重于欧素在COPD病变发生中的作用.
- 分析目前对COPD中乙素生物标志物 (血液和唾液) 的研究.
- 检查新兴的生物疗法,特别是针对IL-5,IL-4和IL-13的单克隆抗体.
主要成果:
- 乙酸性炎症是COPD的独特表型,与增加的呼吸道重塑有关.
- 乙氨基酸计数作为预测COPD预后和指导皮质类固醇治疗的潜在生物标志物.
- 针对特定白内素的单克隆抗体正在研究用于治疗T2高的COPD表型.
结论:
- 乙性COPD代表了一种特定的内型,具有独特的病理特征.
- 生物标志物,如乙酸细胞计数,对于COPD个性化治疗策略至关重要.
- 有针对性的生物疗法对治疗eosinophilic COPD有希望,因此需要进一步的临床研究.
相关概念视频
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:26COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K